Search

Your search keyword '"de Ramón, E"' showing total 6 results
Start Over Author "de Ramón, E" Topic humans
6 results on '"de Ramón, E"'

1. Nonrenal disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospective, randomized, open-label, parallel-group clinical trial

Author

Ginzler, Em, Wofsy, D, Isenberg, D, Gordon, C, Lisk, L, Dooley, Ma, ALMS Group: Abud, C, Adler, S, Alarcón, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Contreras, G, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sanchez Guerrero, J, Roman, Js, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesar, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, and Zoruba, D.

Subjects
Adult, Male, medicine.medical_specialty, Cyclophosphamide, Immunology, Lupus nephritis, Mycophenolate, Gastroenterology, Severity of Illness Index, Mycophenolic acid, law.invention, Rheumatology, Randomized controlled trial, Prednisone, law, Internal medicine, medicine, Immunology and Allergy, Humans, Pharmacology (medical), Prospective Studies, skin and connective tissue diseases, Glucocorticoids, business.industry, Anti-Inflammatory Agents, Non-Steroidal, Remission Induction, Complement System Proteins, Mycophenolic Acid, medicine.disease, Lupus Nephritis, Surgery, Clinical trial, Treatment Outcome, Antibodies, Antinuclear, Injections, Intravenous, Drug Therapy, Combination, Female, business, Immunosuppressive Agents, medicine.drug, Kidney disease
Abstract

To assess the effect of mycophenolate mofetil compared with intravenous pulses of cyclophosphamide on the nonrenal manifestations of lupus nephritis.Patients with active lupus nephritis (renal biopsy class III, IV, or V) were recruited for the study (n = 370) and treated with mycophenolate mofetil (target dosage 3 gm/day) or intravenous cyclophosphamide (0.5-1.0 gm/m(2)/month), plus tapered prednisone, for 24 weeks. Nonrenal outcomes were determined using measures of whole body disease activity, including the British Isles Lupus Assessment Group (BILAG) disease activity index, the Safety of Estrogens in Lupus Erythematosus: National Assessment (SELENA) version of the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and immunologic variables.Both treatments were effective on whole body disease activity in the systems examined, as indicated by changes in the classic BILAG index. With either treatment, remission was induced, notably in the mucocutaneous, musculoskeletal, cardiovascular/respiratory, and vasculitis systems, and flares were rare, as measured by the SELENA-SLEDAI. Levels of complement C3, C4, and CH50 and titers of anti-double-stranded DNA antibodies were normalized after treatment with either mycophenolate mofetil or intravenous cyclophosphamide.In addition to the efficacy of both treatments on the renal system, this analysis showed that remission could also be induced in other systems. There was no clear difference in efficacy between mycophenolate mofetil and intravenous cyclophosphamide in ameliorating either the renal or nonrenal manifestations. Mycophenolate mofetil is, therefore, a suitable alternative to cyclophosphamide for the treatment of renal and nonrenal disease manifestations in patients with biopsy-proven lupus nephritis.

Published
2010

2. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

Author

Appel, Gb, Contreras, G, Dooley, Ma, Ginzler, Em, Isenberg, D, Jayne, D, Li, Ls, Mysler, E, Sánchez Guerrero, J, Solomons, N, Wofsy, D, Aspreva Lupus Management Study Group: Abud, C, Adler, S, Alarcón, G, Albuquerque, E, Almeida, F, Alvarellos, A, Appel, G, Avila, H, Blume, C, Boletis, I, Bonnardeaux, A, Braun, A, Buyon, J, Cervera, R, Chen, N, Chen, S, Da Costa AG, Davids, R, D'Cruz, D, De Ramón, E, Deodhar, A, Doria, Andrea, Dussol, B, Emery, P, Fiechtner, J, Floege, J, Fragoso Loyo, H, Furie, R, Ghazalli, R, Ghossein, C, Gilkeson, G, Ginzler, E, Gordon, C, Grossman, J, Gu, J, Guillevin, L, Hatron, Py, Herrera, G, Hiepe, F, Houssiau, F, Hübscher, O, Hura, C, Kaplan, J, Kirsztajn, G, Kiss, E, Kutty, Ga, Laville, M, Lazaro, M, Lenz, O, Li, L, Lightstone, L, Lim, S, Malaise, M, Manzi, S, Marcos, J, Meyer, O, Monge, P, Naicker, S, Neal, N, Neuwelt, M, Nicholls, K, Olsen, N, Ordi Ros, J, Ostrov, B, Pestana, M, Petri, M, Pokorny, G, Pourrat, J, Qian, J, Radhakrishnan, J, Rovin, B, Sanchez Roman, J, Shanahan, J, Shergy, W, Skopouli, F, Spindler, A, Striebich, C, Sundel, R, Swanepoel, C, Tan, Sy, Tate, G, Tesaŕ, V, Tikly, M, Wang, H, Yahya, R, Yu, X, Zhang, F, and Zoruba, D.

Subjects
Nephrology, Male, medicine.medical_specialty, Cyclophosphamide, Urology, Lupus nephritis, Renal function, Mycophenolic acid, Prednisone, Internal medicine, medicine, Ethnicity, Humans, Adverse effect, business.industry, Racial Groups, General Medicine, Mycophenolic Acid, medicine.disease, Lupus Nephritis, Surgery, Treatment Outcome, Injections, Intravenous, cardiovascular system, Female, business, Immunosuppressive Agents, medicine.drug, Kidney disease, Glomerular Filtration Rate
Abstract

Recent studies have suggested that mycophenolate mofetil (MMF) may offer advantages over intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis, but these therapies have not been compared in an international randomized, controlled trial. Here, we report the comparison of MMF and IVC as induction treatment for active lupus nephritis in a multinational, two-phase (induction and maintenance) study. We randomly assigned 370 patients with classes III through V lupus nephritis to open-label MMF (target dosage 3 g/d) or IVC (0.5 to 1.0 g/m(2) in monthly pulses) in a 24-wk induction study. Both groups received prednisone, tapered from a maximum starting dosage of 60 mg/d. The primary end point was a prespecified decrease in urine protein/creatinine ratio and stabilization or improvement in serum creatinine. Secondary end points included complete renal remission, systemic disease activity and damage, and safety. Overall, we did not detect a significantly different response rate between the two groups: 104 (56.2%) of 185 patients responded to MMF compared with 98 (53.0%) of 185 to IVC. Secondary end points were also similar between treatment groups. There were nine deaths in the MMF group and five in the IVC group. We did not detect significant differences between the MMF and IVC groups with regard to rates of adverse events, serious adverse events, or infections. Although most patients in both treatment groups experienced clinical improvement, the study did not meet its primary objective of showing that MMF was superior to IVC as induction treatment for lupus nephritis.

Published
2009

3. Investigation of TLR5 and TLR7 as candidate genes for susceptibility to systemic lupus erythematosus

Author

Elena Sanchez, Jl, Callejas-Rubio, Jm, Sabio, Ma, Gónzalez-Gay, Jimenez-Alonso J, Micó L, de Ramón E, Camps M, Suarez A, Gutierrez C, Garcia-Portales R, Tolosa C, Ortego-Centeno N, Sánchez-Román J, Fj, Garcia-Hernández, Mf, Gónzalez-Escribano, and Martin J

Subjects
Toll-Like Receptor 5, Toll-Like Receptor 7, Case-Control Studies, Odds Ratio, Humans, Lupus Erythematosus, Systemic, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, White People
Abstract

The aim of this study was to evaluate the relevance of genetic variants of TLR5 (rs5744168) and TLR7 (rs179008) gene in systemic lupus erythematosus (SLE) in a Spanish population.Our study population consisted of 752 SLE patients and 1107 healthy controls. All individual were of Spanish Caucasian origin. The TLR5 and TLR7 polymorphisms were genotyped using a PCR system with pre-developed TaqMan allelic discrimination assay.No statistically significant differences were observed when the allele and genotype distribution of TLR5 rs5744168 and TLR7 rs179008 polymorphisms was compared between SLE patients and healthy controls. A significant increase frequency in the CC genotype of the TLR5 rs5744168 polymorphism among SLE patients without nephritis was found (93% vs. 87% in SLE patients with nephritis, p=0.03, OR=2.11 95%CI 0.93-3.51). However, this difference did not reach statistical significance in the allele frequencies (p=0.08).These results suggest that the tested variations of TLR5 and TLR7 genes do not confer a relevant role in the susceptibility or severity to SLE in the Spanish population.

4. Analysis of ancestral and functionally relevant CD5 variants in systemic lupus erythematosus patients

Author

Miguel A. González-Gay, María Carmen Cenit, Mario Martínez-Florensa, Carles Tolosa, Noelia Armiger, Ana Suárez, Francisco Hernandez, Elena Carnero-Montoro, Javier Martín, Francisco Lozano, Norberto Ortego-Centeno, Enrique de Ramón, Elena Bosch, Miguel Caballero-Baños, M.T. Arias, José Mario Sabio, Daniel Benitez, Marta Consuegra, Lizette Bonet, Universidad de Cantabria, Universitat de Barcelona, Ministerio de Economía y Competitividad (España), Generalitat de Catalunya, Junta de Andalucía, European Commission, Instituto de Salud Carlos III, [Cenit,MC, Martín,J] Instituto de Parasitología y Biomedicina López-Neyra, Consejo Superior de Investigaciones Científicas (CSIC), Granada, Spain. [Martínez-Florensa,M] ImmunNovative Developments, Barcelona, Spain. [Martínez-Florensa,M, Consuegra,M, Bonet,L, Armiger,N, Benitez,D, Lozano,F] Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain. [Carnero-Montoro,E, Bosch,L] Institut de Biologia Evolutiva (CSIC-Universitat Pompeu Fabra), Departament de Ciències Experimentals i de la Salut, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain. [Caballero-Baños,M, Arias,MT, Lozano,F] Department of Immunology, Hospital Clínic de Barcelona, Barcelona, Spain. [Ortego-Centeno,N] Department of Internal Medicine, Hospital Clínico San Cecilio, Granada, Spain. [de Ramón,E] Department of Internal Medicine, Hospital Carlos Haya, Málaga, Spain. [Sabio,JM] Department of Internal Medicine, Hospital Virgen de las Nieves, Granada, Spain. [García–Hernández,FJ] Department of Internal Medicine, Hospital Virgen del Rocío, Seville, Spain. [Tolosa,C] Department of Internal Medicine, Hospital Parc Taulí, Sabadell, Spain. [Suárez,A] Department of Functional Biology, Immunology Area, Faculty of Medicine, University of Oviedo, Oviedo, Spain. [González-Gay,MA] Department of Rheumatology, Hospital Marques de Valdecilla, IFIMAV, Santander, Spain. [Lozano,F] Departament de Biologia Cel•lular, Immunologia i Neurociencies, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain., and This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucı´a [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM]

Subjects
Phenomena and Processes::Immune System Phenomena::Immunity::Autoimmunity [Medical Subject Headings], Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic::Lupus Nephritis [Medical Subject Headings], T-Lymphocytes, Lymphocyte, Lupus nephritis, Polimorfismo genético, Autoimmunity, Lymphocyte Activation, medicine.disease_cause, Phenomena and Processes::Genetic Phenomena::Genotype::Haplotypes [Medical Subject Headings], Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings], immune system diseases, Nefritis lúpica, Medicine and Health Sciences, Lupus Erythematosus, Systemic, Immunologia, Lymphocytes, Genetics, Multidisciplinary, Estudios de casos y controles, Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Case-Control Studies [Medical Subject Headings], Diseases::Immune System Diseases::Autoimmune Diseases::Lupus Erythematosus, Systemic [Medical Subject Headings], Predisposición genética a la enfermedad, Lupus Nephritis, Humanos, medicine.anatomical_structure, Medicine, Haplotipos, Phenomena and Processes::Genetic Phenomena::Genotype [Medical Subject Headings], Alelos, Nephritis, Research Article, Genotype, Inflammatory Diseases, T cell, Science, Immunology, Antígenos CD5, Single-nucleotide polymorphism, Autoinmunidad, CD5 Antigens, Limfòcits, Diseases::Pathological Conditions, Signs and Symptoms::Pathologic Processes::Disease Attributes::Disease Susceptibility::Genetic Predisposition to Disease [Medical Subject Headings], Rheumatology, Lupus eritematós sistèmic, Lupus eritematoso sistémico, medicine, Humans, Genetic Predisposition to Disease, Allele, Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Alleles [Medical Subject Headings], Alleles, Polymorphism, Genetic, Lupus erythematosus, Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::Glycoproteins::Membrane Glycoproteins::Antigens, CD58 [Medical Subject Headings], business.industry, Haplotype, Biology and Life Sciences, Phenomena and Processes::Genetic Phenomena::Genetic Variation::Polymorphism, Genetic [Medical Subject Headings], medicine.disease, Haplotypes, Case-Control Studies, Lupus eritematós, business, Genotipo
Abstract

Cénit, M.C. et al., CD5 plays a crucial role in autoimmunity and is a well-established genetic risk factor of developing RA. Recently, evidence of positive selection has been provided for the CD5 Pro224-Val471 haplotype in East Asian populations. The aim of the present work was to further analyze the functional relevance of non-synonymous CD5 polymorphisms conforming the ancestral and the newly derived haplotypes (Pro224-Ala471 and Pro224-Val471, respectively) as well as to investigate the potential role of CD5 on the development of SLE and/or SLE nephritis, This work was supported by grants from the Spanish Ministerio de Economía y Competitividad [SAF2010-19717 to FL, SAF2009-11110 to JM, SAF2011-29239, and BFU2008-01046 to EB], Generalitat de Catalunya [2009SGR00252 to FL, and 2009SGR1101 to EB], Junta de Andalucía [CTS-4977], and Instituto de Salud Carlos III and Fondo Europeo de Desarrollo Regional/FEDER [RD12/0009/0004 to JM].

Published
2014

5. Systemic lupus erythematosus in Europe at the change of the millennium: lessons from the 'Euro-Lupus Project'

Author

Cervera, R, ABARCA-COSTALAGO, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, Ao, Bacarelli, Mr, Bellisai, F, Bernardino, I, BIERNAT-KALUZA, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, Mt, Carcassi, C, Cattaneo, R, Cauli, A, CHWALINSKA-SADOWSKA, H, Contu, L, Cosyns, Jp, Danieli, Mg, Dcruz, D, Depresseux, G, Direskeneli, H, Domenech, I, Espinosa, G, FERNANDEZ-NEBRO, A, Ferrara, Gb, Font, J, Frutos, Ma, Galeazzi, M., GARCIA-CARRASCO, M, GARCIA IGLESIAS MF, GARCIA-TOBARUELA, A, George, J, Gil, A, GONZALEZ-SANTOS, P, Grana, M, Gul, A, Haga, Hj, DE HARO-LIGER, M, Houssiau, F, Hughes, Gr, Ingelmo, M, JEDRYKA-GORAL, A, Khamashta, Ma, Lavilla, P, Levi, Y, LOPEZ-DULPA, M, LOPEZ-SOTO, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perello, I, Petera, P, Petrovic, R, Piette, Jc, Pintado, V, DE PITA, O, Popovic, R, Pucci, G, Puddu, P, DE RAMON, E, RAMOS-CASALS, M, RODRIGUEZ-ANDREU, J, RUIZ-IRASTORZA, G, SANCHEZ-LORA, J, Sanna, G, Scorza, R, Sebastiani, Gd, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, Ra, Smolen, J, Tincani, A, Tokgoz, G, URBANO-MARQUEZ, A, Vasconcelos, C, Vazquez, Jj, Veronesi, J, Vianna, J, Vivancos, J, UCL - MD/MINT - Département de médecine interne, UCL - (SLuc) Service de rhumatologie, UCL - MD/MNOP - Département de morphologie normale et pathologique, UCL - (SLuc) Service d'anatomie pathologique, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D́cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastorza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastiani, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianna, J, and Vivancos, J

Subjects
Male, medicine.medical_specialty, Prognosi, Epidemiology, Immunology, Systemic lupus erythematosu, Disease, Prognostic factors, Autoimmune Disease, Follow-Up Studie, Autoimmune Diseases, Cohort Studies, Systemic lupus erythematosus, immune system diseases, medicine, Immunology and Allergy, Humans, Lupus Erythematosus, Systemic, Prospective Studies, Age of Onset, Mortality, Prospective cohort study, skin and connective tissue diseases, Survival rate, Prognostic factor, business.industry, medicine.disease, Prognosis, Europe, Survival Rate, Prospective Studie, Family medicine, Antibodies, Antinuclear, Cohort, Female, Cohort Studie, Age of onset, Morbidity, business, Human, Cohort study, Follow-Up Studies
Abstract

The "Euro-Lupus Cohort" is composed by 1000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium-the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors. © 2005 Elsevier B.V. All rights reserved.

Published
2006

6. Lessons from the 'Euro-Lupus Cohort'

Author

Cervera, R., Abarca Costalago, M., Abramovicz, D., Allegri, F., PASQUALE ANNUNZIATA, Aydintug, Ao, Bacarelli, Mr, Bellisai, F., Bernardino, I., Biernat Kaluza, E., Blockmans, D., Boki, K., LUISA BRACCI, Campanella, V., Camps, Mt, Carcassi, C., Cattaneo, R., Cauli, A., Chwalinska Sadowska, H., Contu, L., Cosyns, Jp, Danieli, Mg, D Cruz, D., Depresseux, G., Direskeneli, H., Domènech, I., Espinosa, G., Fernández Nebro, A., Ferrara, Gb, Font, J., Frutos, Ma, MAURO GALEAZZI, García Carrasco, M., GARCÍA IGLESIAS MF, García Tobaruela, A., George, J., Gil, A., González Santos, P., Grana, M., Gül, A., Haga, Hj, Haro Liger, M., Houssiau, F., Hughes, Gr, Ingelmo, M., Jedryka Góral, A., Khamashta, Ma, Lavilla, P., Levi, Y., López Dupla, M., López Soto, A., Maldykowa, H., Marcolongo, R., Mathieu, A., GABRIELLA MOROZZI, Nicolopoulou, N., Papasteriades, C., Passiu, G., Perelló, I., Petera, P., Petrovic, R., Piette, Jc, Pintado, V., Pita, O., Popovic, R., Pucci, G., Puddu, P., Ramón, E., Ramos Casals, M., Rodríguez Andreu, J., Ruiz Irastroza, G., Sánchez Lora, J., Sanna, G., Scorza, R., Sebastini, Gd, Sherer, Y., Shoenfeld, Y., Simpatico, A., Sinico, Ra, Smolen, J., Tincani, A., Tokgöz, G., Urbano Márquez, A., Vasconcelos, C., Vázquez, Jj, Veronesi, M., Vianni, J., Vivancos, J., EUROPEAN WORKING PARTY ON SYSTEMIC LUPUS ERYTHEMATOSUS, Cervera, R, Abarca Costalago, M, Abramovicz, D, Allegri, F, Annunziata, P, Aydintug, A, Bacarelli, M, Bellisai, F, Bernardino, I, Biernat Kaluza, E, Blockmans, D, Boki, K, Bracci, L, Campanella, V, Camps, M, Carcassi, C, Cattaneo, R, Cauli, A, Chwalinska Sadowska, H, Contu, L, Cosyns, J, Danieli, M, D'Cruz, D, Depresseux, G, Direskeneli, H, Domènech, I, Espinosa, G, Fernández Nebro, A, Ferrara, G, Font, J, Frutos, M, Galeazzi, M, García Carrasco, M, García Iglesias, M, García Tobaruela, A, George, J, Gil, A, González Santos, P, Grana, M, Gül, A, Haga, H, de Haro Liger, M, Houssiau, F, Hughes, G, Ingelmo, M, Jedryka Góral, A, Khamashta, M, Lavilla, P, Levi, Y, López Dupla, M, López Soto, A, Maldykowa, H, Marcolongo, R, Mathieu, A, Morozzi, G, Nicolopoulou, N, Papasteriades, C, Passiu, G, Perelló, I, Petera, P, Petrovic, R, Piette, J, Pintado, V, de Pita, O, Popovic, R, Pucci, G, Puddu, P, de Ramón, E, Ramos Casals, M, Rodríguez Andreu, J, Ruiz Irastroza, G, Sánchez Lora, J, Sanna, G, Scorza, R, Sebastini, G, Sherer, Y, Shoenfeld, Y, Simpatico, A, Sinico, R, Smolen, J, Tincani, A, Tokgöz, G, Urbano Márquez, A, Vasconcelos, C, Vázquez, J, Veronesi, M, Vianni, J, and Vivancos, J

Subjects
Adult, Male, Adolescent, Prognosi, Middle Aged, Prognosis, Cohort Studies, Europe, Survival Rate, Prospective Studie, Antibodies, Antinuclear, Humans, Lupus Erythematosus, Systemic, Female, Prospective Studies, Cohort Studie, Age of Onset, Human
Abstract

The "Euro-Lupus Cohort" is composed by 1,000 patients with systemic lupus erythematosus (SLE) that have been followed prospectively since 1991. These patients have been gathered by a European consortium - the "Euro-Lupus Project Group". This consortium was originated as part of the network promoted by the "European Working Party on SLE", a working group created in 1990 in order to promote research in Europe on the different problems related to this disease. The "Euro-Lupus Cohort" provides an updated information on the SLE morbidity and mortality characteristics in the present decade as well as defines several clinical and immunological prognostic factors.

Published
2002

Catalog

Books, media, physical & digital resources
See catalog results